Abstract
Spinocerebellar ataxia type 10 (SCA10) is an autosomal-dominant disorder caused by an expanded pentanucleotide repeat in the ATXN10 gene. This repeat expansion, when fully penetrant, has a size of 850 to 4500 repeats. It has been shown that the repeat composition can be a modifier of disease, e.g., seizures.
Here, we describe a Hispanic kindred in which we identified both pure (ATTCT)n expansions and mixed (ATTCT)n-(ATTCC)n in the same family. We used No-Amp targeted sequencing and optical genome mapping to decipher the composition of these repeat expansions. We found a considerable degree of mosaicism in the repeat expansion. This mosaicism was confirmed in skin fibroblasts from ATXN10 carriers with RNAScope in situ hybridization. All affected family members with the mixed ATXN10 repeat expansion showed typical clinical signs of spinocerebellar ataxia and epilepsy. In contrast, individuals with the pure ATXN10 expansion present with Parkinson’s disease or are unaffected even more than 20 years older than the average age at onset for SCA10.
Our findings suggest that the pure (ATTCT)n expansion is non-pathogenic while repeat interruptions, e.g., (ATTCC)n, are necessary to cause SCA10. This mechanism has been recently described for several other repeat expansions, including SCA31 (BEAN1), SCA37 (DAB1), and three loci for benign adult familial myoclonic epilepsy BAFME (SAMD12, TNRC6A, RAPGEF2). Therefore, long-read sequencing and optical genome mapping of the entire genomic structure of repeat expansions is critical for clinical practice, and genetic counseling as variations in the repeat can affect disease penetrance, symptoms, and disease trajectory.
Competing Interest Statement
I. McLaughlin, Y.-C. Tsai, J. S. Ziegle are employees and shareholders of Pacific Biosciences. K. Hong, J. C. Y. Lai, J. Lee, and M. Gallagher are employees and shareholders of Bionano Genomics. B. Schuele, F. Jimenez Gil, J. Palafox Vasquez, F. Zafar, C. A. Morato Torres, F. Torres, T. Ashizawa, J. Fernandez-Ruiz, A. Chirino-Perez, A.O. Romero-Molina declare no competing interests.
Funding Statement
Chan Zuckerberg Initiative supplemental funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committee of Stanford University School of Medicine (Stanford IRB-48895). All participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
